Free company analysis covering financials, risk flags, competitive position, and opportunity scoring. Keytruda-powered oncology leader. $64B+ revenue, facing 2028 Keytruda LOE. Aggressive $11B Prometheus + $10.8B Harpoon M&A pipeline.
Keytruda-powered oncology leader. $64B+ revenue, facing 2028 Keytruda LOE. Aggressive $11B Prometheus + $10.8B Harpoon M&A pipeline.
Free 1-page brief delivered in minutes. Full 20-page report available for purchase.
Get Free Brief → Buy Full Report ($39.20 launch)